1. Home
  2. ATYR vs QUAD Comparison

ATYR vs QUAD Comparison

Compare ATYR & QUAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • QUAD
  • Stock Information
  • Founded
  • ATYR 2005
  • QUAD 1971
  • Country
  • ATYR United States
  • QUAD United States
  • Employees
  • ATYR N/A
  • QUAD N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • QUAD Publishing
  • Sector
  • ATYR Health Care
  • QUAD Consumer Discretionary
  • Exchange
  • ATYR Nasdaq
  • QUAD Nasdaq
  • Market Cap
  • ATYR 327.0M
  • QUAD 287.7M
  • IPO Year
  • ATYR 2015
  • QUAD 2010
  • Fundamental
  • Price
  • ATYR $2.96
  • QUAD $5.61
  • Analyst Decision
  • ATYR Strong Buy
  • QUAD Strong Buy
  • Analyst Count
  • ATYR 6
  • QUAD 2
  • Target Price
  • ATYR $18.60
  • QUAD $10.15
  • AVG Volume (30 Days)
  • ATYR 1.5M
  • QUAD 223.1K
  • Earning Date
  • ATYR 03-13-2025
  • QUAD 04-29-2025
  • Dividend Yield
  • ATYR N/A
  • QUAD 4.01%
  • EPS Growth
  • ATYR N/A
  • QUAD N/A
  • EPS
  • ATYR N/A
  • QUAD N/A
  • Revenue
  • ATYR $235,000.00
  • QUAD $2,672,200,000.00
  • Revenue This Year
  • ATYR $1,387.23
  • QUAD N/A
  • Revenue Next Year
  • ATYR $873.22
  • QUAD N/A
  • P/E Ratio
  • ATYR N/A
  • QUAD N/A
  • Revenue Growth
  • ATYR N/A
  • QUAD N/A
  • 52 Week Low
  • ATYR $1.42
  • QUAD $4.06
  • 52 Week High
  • ATYR $4.66
  • QUAD $9.13
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 37.05
  • QUAD 45.11
  • Support Level
  • ATYR $3.20
  • QUAD $5.29
  • Resistance Level
  • ATYR $3.94
  • QUAD $5.58
  • Average True Range (ATR)
  • ATYR 0.25
  • QUAD 0.16
  • MACD
  • ATYR -0.08
  • QUAD 0.05
  • Stochastic Oscillator
  • ATYR 9.33
  • QUAD 69.57

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About QUAD Quad Graphics Inc

Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market.

Share on Social Networks: